By Fineline Cube 
Suzhou AsiFlyer Biotechnology Co., Ltd. announced that on August 1, 2026 it signed a technology licensing agreement with ShanghaiTech University, granting AsiFlyer an exclusive, worldwide technology license for patent PCT/CN2025/119660.
Deal Milestone
| Item | Detail |
|---|---|
| Licensee | Suzhou AsiFlyer Biotechnology Co., Ltd. |
| Licensor | ShanghaiTech University |
| Agreement Type | Technology licensing agreement |
| Licensed Asset | Patent PCT/CN2025/119660 |
| Territory | Exclusive, worldwide |
| Signing Date | 1 Aug 2026 |
| Application | AsiFlyer’s first AI+ drug pipeline — a novel recombinant botulinum toxin protein drug |
Product Profile & Innovation
- Modality: AI‑designed novel recombinant botulinum toxin protein drug — the lead asset of AsiFlyer’s first AI+ drug pipeline
- Unmet Needs Addressed: Designed to overcome limitations of existing commercial botulinum toxin type A products, including:
- Drug resistance — immunogenicity and neutralizing antibodies that reduce efficacy over repeated treatments
- Restricted indication expansion — constraints limiting approved and off‑label uses
- Differentiation: Molecular design driven by artificial intelligence rather than conventional strain‑based development
Industry–University Partnership Model
| Role | Responsible Party | Capability |
|---|---|---|
| Molecular design of the drug | ShanghaiTech University | AI‑powered de novo protein design |
| In vitro and in vivo activity evaluation | Suzhou AsiFlyer Biotechnology | GLP‑like ProtFRET and GSRDimi platforms |
| Risk management | Joint | Comprehensive gap and technical feasibility analyses, significantly mitigating the project’s technical risks |
Market Impact & Outlook
- AI+ Toxin Engineering: The global botulinum toxin market remains dominated by type A products with known immunogenicity limits. An AI‑designed recombinant toxin targeting drug resistance could open a differentiated next‑generation segment spanning aesthetics and therapeutics.
- Worldwide Exclusive Rights: The worldwide scope of the license gives AsiFlyer full freedom to develop, partner, or commercialize the asset internationally without geographic carve‑outs.
- De‑Risked Development Model: Splitting design (ShanghaiTech) and GLP‑like activity validation (AsiFlyer’s ProtFRET and GSRDimi platforms) creates an iterative design–test loop, with formal gap and feasibility analyses reducing technical risk ahead of preclinical advancement.
- Pipeline Genesis: As the first asset in AsiFlyer’s AI+ pipeline, the program establishes the company’s platform credibility in AI‑driven protein drug discovery.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding preclinical evaluation, development timelines, and commercialization of the AI‑designed recombinant botulinum toxin. Actual results may differ due to risks including research outcomes, regulatory timelines, manufacturing scale‑up, market adoption, and competitive dynamics.-Fineline Info & Tech